Evommune to present Phase 2a EVO301 AD data at EADV 2026; Phase 2b planned mid-2027

Evommune, Inc.

Phase 2a EVO301 (IL-18 binding protein) atopic dermatitis data in late-breaker Oct 1 at EADV Vienna; presenter Dr. Mark G. Lebwohl.
Topline results previously reported this year; Phase 2b dose-ranging study in moderate-to-severe AD expected to start mid-2027.
EVO301 targets IL-18 upstream of Th2 axis, modulating Th1, Th2, Th17/22 and innate inflammatory pathways.
CEO Luis Peña cites 29M patients in 7 major markets needing advanced AD therapy; IL-18 offers broad-spectrum potential.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.